NCT02491099View on ClinicalTrials.gov

A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2028

Conditions
HER2/Neu+ Uterine Serous Carcinoma
Interventions
DRUG

Afatinib

Afatinib, 40 mg orally once daily on a 21 day cycle for the first 12 weeks, then every 28 days for subsequent cycles until progression

Trial Locations (3)

85724

COMPLETED

University of Arizona Cancer Center, Tucson

06510

RECRUITING

Yale New Haven Hospital, New Haven

02114

COMPLETED

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

Yale University

OTHER